ReviewDialogues in clinical neuroscience2009
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine.
Review in Dialogues in clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome.Brain & development · 2017Trial
- The Role of the 5-HTTLPR Gene Variation of the SLC6A4 Serotonergic System in the Development of Addictive Disorders: A Narrative Review.Consortium psychiatricum · 2025Review
- The neurobiology of plant-based therapeutics in women's reproductive health: mechanisms, efficacy, and clinical translation.Frontiers in nutrition · 2025Review
- The Approach to Patients with Disorders of Sex Development (DSD) in the Era of Precision Medicine: The Careful Use of Terminology.TouchREVIEWS in endocrinology · 2024Article
- Precision child and adolescent psychiatry: reductionism, fad, or change of identity of the discipline?European child & adolescent psychiatry · 2024Article
- Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.Translational psychiatry · 2022Review
- Four Actionable Bottlenecks and Potential Solutions to Translating Psychiatric Genetics Research: An Expert Review.Public health genomics · 2020Review
- BDNF Val66Met Polymorphism Is Related to Motor System Function After Stroke.Physical therapy · 2016Article
- Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments.Progress in neurobiology · 2015Review
- Perceptions of genetic testing and genomic medicine among drug users.The International journal on drug policy · 2015Article
- Personalized therapies in psychiatry: promises, pitfalls and perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2015Article
- Biomarkers: symptoms, survivorship, and quality of life.Seminars in oncology nursing · 2012Review
- Viewing the elephant from 200 feet: reconstructing the schizophrenia syndrome.Schizophrenia research · 2011Article
- Pharmacokinetic/ pharmacodynamic-driven drug development.The Mount Sinai journal of medicine, New YorkReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We currently rely on large randomized controlled trials and meta-analyses to make clinical decisions; this places us at a risk of discarding subgroup or individually specific treatment options owing to their failure to prove efficacious across entire populations. There is a new era emerging in personalized medicine that will focus on individual differences that are not evident phenomenologically. Much research is directed towards identifying genes, endophenotypes, and biomarkers of disease that will facilitate diagnosis and predict treatment outcome. We are at the threshold of being able to predict treatment response, primarily through genetics and neuroimaging. In this review we discuss the most promising markers of treatment response and adverse effects emerging from the areas of pharmacogenetics and neuroimaging in depression and schizophrenia.
Indexed as
Identifiers
20135894PMC3181934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.